• Feraccru granted major extension to approval in Switzerland firstwordpharma
    April 25, 2019
    London, UK, 24th April 2019: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru® ...
  • Norgine launches Shield’s Feraccru in the UK pharmatimes
    December 07, 2018
    Norgine has launched Feraccru across the UK to treat patients with iron deficiency anaemia, having picked up rights to sell the drug from Shield Therapeutics earlier this year.
PharmaSources Customer Service